Cell-Based Therapy for Myocardial Dysfunction After Fontan Operation in Hypoplastic Left Heart Syndrome

Wanek Program Regenerative Medicine Pipeline, Muhammad Y Qureshi, Allison K Cabalka, Shakila P Khan, Donald J Hagler, Dawit T Haile, Bryan C Cannon, Timothy M Olson, Susana Cantero-Peral, Allan B Dietz, Darcie J Radel, Nathan W Taggart, Angela M Kelle, Vilmarie Rodriguez, Joseph A Dearani, Patrick W O'Leary

Research output: Contribution to journalArticle

Abstract

Myocardial dysfunction after Fontan palliation for univentricular congenital heart disease is a challenging clinical problem. The medical treatment has a limited impact, with cardiac transplant being the ultimate management step. Cell-based therapies are evolving as a new treatment for heart failure. Phase 1 clinical trials using regenerative therapeutic strategies in congenital heart disease are ongoing. We report the first case of autologous bone marrow-derived mononuclear cell administration for ventricular dysfunction, 23 years after Fontan operation in a patient with hypoplastic left heart syndrome. The cells were delivered into the coronary circulation by cardiac catheterization. Ventricular size decreased and several parameters reflecting ventricular function improved, with maximum change noted 3 months after cell delivery. Such regenerative therapeutic options may help in delaying and preventing cardiac transplant.

Original languageEnglish (US)
Pages (from-to)185-191
Number of pages7
JournalMayo Clinic proceedings. Innovations, quality & outcomes
Volume1
Issue number2
DOIs
StatePublished - Sep 2017
Externally publishedYes

Fingerprint

Hypoplastic Left Heart Syndrome
Fontan Procedure
Cell- and Tissue-Based Therapy
Heart Diseases
Transplants
Ventricular Dysfunction
Coronary Circulation
Clinical Trials, Phase I
Ventricular Function
Cardiac Catheterization
Treatment Failure
Therapeutics
Heart Failure
Bone Marrow

Cite this

Wanek Program Regenerative Medicine Pipeline, Qureshi, M. Y., Cabalka, A. K., Khan, S. P., Hagler, D. J., Haile, D. T., ... O'Leary, P. W. (2017). Cell-Based Therapy for Myocardial Dysfunction After Fontan Operation in Hypoplastic Left Heart Syndrome. Mayo Clinic proceedings. Innovations, quality & outcomes, 1(2), 185-191. https://doi.org/10.1016/j.mayocpiqo.2017.07.002
Wanek Program Regenerative Medicine Pipeline ; Qureshi, Muhammad Y ; Cabalka, Allison K ; Khan, Shakila P ; Hagler, Donald J ; Haile, Dawit T ; Cannon, Bryan C ; Olson, Timothy M ; Cantero-Peral, Susana ; Dietz, Allan B ; Radel, Darcie J ; Taggart, Nathan W ; Kelle, Angela M ; Rodriguez, Vilmarie ; Dearani, Joseph A ; O'Leary, Patrick W. / Cell-Based Therapy for Myocardial Dysfunction After Fontan Operation in Hypoplastic Left Heart Syndrome. In: Mayo Clinic proceedings. Innovations, quality & outcomes. 2017 ; Vol. 1, No. 2. pp. 185-191.
@article{61e33624323f4a7684e66710af61334c,
title = "Cell-Based Therapy for Myocardial Dysfunction After Fontan Operation in Hypoplastic Left Heart Syndrome",
abstract = "Myocardial dysfunction after Fontan palliation for univentricular congenital heart disease is a challenging clinical problem. The medical treatment has a limited impact, with cardiac transplant being the ultimate management step. Cell-based therapies are evolving as a new treatment for heart failure. Phase 1 clinical trials using regenerative therapeutic strategies in congenital heart disease are ongoing. We report the first case of autologous bone marrow-derived mononuclear cell administration for ventricular dysfunction, 23 years after Fontan operation in a patient with hypoplastic left heart syndrome. The cells were delivered into the coronary circulation by cardiac catheterization. Ventricular size decreased and several parameters reflecting ventricular function improved, with maximum change noted 3 months after cell delivery. Such regenerative therapeutic options may help in delaying and preventing cardiac transplant.",
author = "{Wanek Program Regenerative Medicine Pipeline} and Qureshi, {Muhammad Y} and Cabalka, {Allison K} and Khan, {Shakila P} and Hagler, {Donald J} and Haile, {Dawit T} and Cannon, {Bryan C} and Olson, {Timothy M} and Susana Cantero-Peral and Dietz, {Allan B} and Radel, {Darcie J} and Taggart, {Nathan W} and Kelle, {Angela M} and Vilmarie Rodriguez and Dearani, {Joseph A} and O'Leary, {Patrick W}",
year = "2017",
month = "9",
doi = "10.1016/j.mayocpiqo.2017.07.002",
language = "English (US)",
volume = "1",
pages = "185--191",
journal = "Mayo Clinic proceedings. Innovations, quality & outcomes",
issn = "2542-4548",
number = "2",

}

Wanek Program Regenerative Medicine Pipeline, Qureshi, MY, Cabalka, AK, Khan, SP, Hagler, DJ, Haile, DT, Cannon, BC, Olson, TM, Cantero-Peral, S, Dietz, AB, Radel, DJ, Taggart, NW, Kelle, AM, Rodriguez, V, Dearani, JA & O'Leary, PW 2017, 'Cell-Based Therapy for Myocardial Dysfunction After Fontan Operation in Hypoplastic Left Heart Syndrome', Mayo Clinic proceedings. Innovations, quality & outcomes, vol. 1, no. 2, pp. 185-191. https://doi.org/10.1016/j.mayocpiqo.2017.07.002

Cell-Based Therapy for Myocardial Dysfunction After Fontan Operation in Hypoplastic Left Heart Syndrome. / Wanek Program Regenerative Medicine Pipeline; Qureshi, Muhammad Y; Cabalka, Allison K; Khan, Shakila P; Hagler, Donald J; Haile, Dawit T; Cannon, Bryan C; Olson, Timothy M; Cantero-Peral, Susana; Dietz, Allan B; Radel, Darcie J; Taggart, Nathan W; Kelle, Angela M; Rodriguez, Vilmarie; Dearani, Joseph A; O'Leary, Patrick W.

In: Mayo Clinic proceedings. Innovations, quality & outcomes, Vol. 1, No. 2, 09.2017, p. 185-191.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cell-Based Therapy for Myocardial Dysfunction After Fontan Operation in Hypoplastic Left Heart Syndrome

AU - Wanek Program Regenerative Medicine Pipeline

AU - Qureshi, Muhammad Y

AU - Cabalka, Allison K

AU - Khan, Shakila P

AU - Hagler, Donald J

AU - Haile, Dawit T

AU - Cannon, Bryan C

AU - Olson, Timothy M

AU - Cantero-Peral, Susana

AU - Dietz, Allan B

AU - Radel, Darcie J

AU - Taggart, Nathan W

AU - Kelle, Angela M

AU - Rodriguez, Vilmarie

AU - Dearani, Joseph A

AU - O'Leary, Patrick W

PY - 2017/9

Y1 - 2017/9

N2 - Myocardial dysfunction after Fontan palliation for univentricular congenital heart disease is a challenging clinical problem. The medical treatment has a limited impact, with cardiac transplant being the ultimate management step. Cell-based therapies are evolving as a new treatment for heart failure. Phase 1 clinical trials using regenerative therapeutic strategies in congenital heart disease are ongoing. We report the first case of autologous bone marrow-derived mononuclear cell administration for ventricular dysfunction, 23 years after Fontan operation in a patient with hypoplastic left heart syndrome. The cells were delivered into the coronary circulation by cardiac catheterization. Ventricular size decreased and several parameters reflecting ventricular function improved, with maximum change noted 3 months after cell delivery. Such regenerative therapeutic options may help in delaying and preventing cardiac transplant.

AB - Myocardial dysfunction after Fontan palliation for univentricular congenital heart disease is a challenging clinical problem. The medical treatment has a limited impact, with cardiac transplant being the ultimate management step. Cell-based therapies are evolving as a new treatment for heart failure. Phase 1 clinical trials using regenerative therapeutic strategies in congenital heart disease are ongoing. We report the first case of autologous bone marrow-derived mononuclear cell administration for ventricular dysfunction, 23 years after Fontan operation in a patient with hypoplastic left heart syndrome. The cells were delivered into the coronary circulation by cardiac catheterization. Ventricular size decreased and several parameters reflecting ventricular function improved, with maximum change noted 3 months after cell delivery. Such regenerative therapeutic options may help in delaying and preventing cardiac transplant.

U2 - 10.1016/j.mayocpiqo.2017.07.002

DO - 10.1016/j.mayocpiqo.2017.07.002

M3 - Article

VL - 1

SP - 185

EP - 191

JO - Mayo Clinic proceedings. Innovations, quality & outcomes

JF - Mayo Clinic proceedings. Innovations, quality & outcomes

SN - 2542-4548

IS - 2

ER -